Yamaguchi‑Fujita Syndrome (Adult‑Onset Still’s Disease)

Overview

Yamaguchi‑Fujita syndrome, more commonly known as Adult‑Onset Still’s Disease (AOSD), is a rare systemic inflammatory disorder that typically presents in young adults. It is characterized by a triad of high‑spiking fevers, a distinctive salmon‑pink rash, and arthralgia/arthritis, along with a constellation of laboratory abnormalities.

Although the disease can affect any age, it most often appears between 16 and 35 years of age, and females are slightly more frequently affected than males (approximately 1.5 : 1). Because the presentation mimics infections, malignancies, and other rheumatologic conditions, the disease is frequently under‑diagnosed.

Prevalence: The estimated incidence ranges from 0.16 to 0.4 cases per 100,000 persons per year worldwide, with higher rates reported in Japan and Europe [1][2].

Symptoms

Symptoms may appear abruptly and can fluctuate between relapsing‑remitting and chronic patterns. The following list captures the most commonly reported manifestations:

• Fever – Daily spiking fevers (≥ 39 °C/102.2 °F) that peak in the late afternoon or early evening and often return to normal within 24 hours.
• Rash – A fleeting, salmon‑pink, maculopapular or urticarial rash that typically appears on the trunk and limbs during fever spikes; it may become more pronounced after a warm shower.
• Arthralgia/Arthritis – Joint pain affecting wrists, knees, ankles, and small joints of the hands; up to 80 % develop chronic polyarthritis.
• Myalgia – Diffuse muscle aches, especially in the thighs and calves.
• Sore throat – Often severe and unresponsive to antibiotics.
• Lymphadenopathy – Enlarged cervical, axillary, or inguinal lymph nodes.
• Hepatomegaly & splenomegaly – Mild enlargement of liver or spleen, sometimes with mild transaminitis.
• Serositis – Pericarditis, pleuritis, or peritoneal inflammation causing chest pain or abdominal discomfort.
• Elevated ferritin – Serum ferritin often > 3,000 ng/mL and may exceed 10,000 ng/mL in severe disease.
• Other possible signs – Pleuritic chest pain, significant weight loss, night sweats, and, rarely, macrophage activation syndrome (MAS) – a life‑threatening hyper‑inflammatory state.

Causes and Risk Factors

The exact cause of AOSD remains unknown, but research suggests a multifactorial process involving genetic susceptibility, abnormal innate immune activation, and possible environmental triggers.

Genetic Factors

• Associations with HLA‑B17, HLA‑B35, and HLA‑DRB1*04 alleles have been reported, indicating a potential role for antigen presentation pathways [3].

Immune Dysregulation

• Excessive production of pro‑inflammatory cytokines—especially interleukin‑1β (IL‑1β), interleukin‑6 (IL‑6), interleukin‑18 (IL‑18), and tumor necrosis factor‑α (TNF‑α)—drives the systemic features.

Environmental Triggers

• Infections with viruses (e.g., Epstein‑Barr virus, parvovirus B19) or bacteria may act as triggers in genetically predisposed individuals, though a direct causal link has not been proven.

Risk Factors

• Age 16–35 years (most cases).
• Female sex (ratio ≈ 1.5 : 1).
• Family history of autoimmune or autoinflammatory diseases (though familial clustering is rare).

Diagnosis

There is no single definitive test for AOSD. Diagnosis is clinical, supported by laboratory findings and the exclusion of mimicking conditions. The most widely used criteria are the Yamaguchi criteria (1992) and the Fautrel criteria (2002).

Yamaguchi Diagnostic Criteria

• Major criteria (need ≥ 2): Fever ≥ 39 °C lasting ≥ 1 week, arthralgia/arthritis ≥ 2 weeks, typical rash, leukocytosis ≥ 10,000 /µL with ≥ 80 % neutrophils.
• Minor criteria (need ≥ 2): Sore throat, lymphadenopathy or splenomegaly, abnormal liver function tests, negative rheumatoid factor (RF) and antinuclear antibody (ANA).
• Diagnosis requires exclusion of infections, malignancy, and other rheumatic diseases.

Laboratory Findings

• Elevated acute‑phase reactants: ESR, CRP.
• Serum ferritin: Frequently > 5 times the upper limit of normal; glycosylated ferritin < 20 % is characteristic.
• Leukocytosis: Neutrophil predominance.
• Negative ANA and RF in > 80 % of patients (helps distinguish from systemic lupus erythematosus or rheumatoid arthritis).

Imaging & Other Tests

• Joint imaging: X‑ray or ultrasound may show early synovitis; later stages can reveal erosions.
• Chest CT / echocardiogram: Evaluate for serositis or pericardial effusion.
• Bone marrow biopsy: Rarely needed, but can help rule out lymphoma if cytopenias are present.

Treatment Options

Treatment aims to control systemic inflammation, prevent joint damage, and reduce the risk of life‑threatening complications such as MAS.

First‑Line Therapies

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) – Useful for mild disease but often insufficient alone.
• Glucocorticoids – Prednisone 0.5–1 mg/kg/day is the cornerstone for moderate‑to‑severe disease; taper is guided by clinical response and inflammatory markers.

Targeted Biologic Agents

When patients are steroid‑dependent or refractory, biologics that block key cytokines are recommended.

• IL‑1 inhibitors: Anakinra (daily subcutaneous), canakinumab (monthly). Demonstrated rapid fever and rash resolution in many series [4].
• IL‑6 receptor antagonist: Tocilizumab (IV or SC). Effective for arthritis and systemic features.
• TNF‑α inhibitors: Etanercept, infliximab, or adalimumab—used less frequently but beneficial for chronic arthritis.

Disease‑Modifying Antirheumatic Drugs (DMARDs)

• Methotrexate – Often added to reduce steroid dose and manage persistent arthritis.
• Azathioprine or leflunomide – Alternative DMARDs for patients intolerant to methotrexate.

Lifestyle & Supportive Measures

• Adequate rest during fever spikes.
• Balanced diet rich in omega‑3 fatty acids (anti‑inflammatory).
• Physical therapy to maintain joint range of motion.
• Vaccinations (influenza, pneumococcal, COVID‑19) – especially important if immunosuppressed.

Living with Yamaguchi‑Fujita Syndrome

Although AOSD is chronic, many patients achieve remission or low disease activity with modern therapy.

Daily Management Tips

• Medication adherence: Use reminders or pill organizers; never stop steroids abruptly.
• Monitor symptoms: Keep a fever‑and‑rash diary; record joint pain scores.
• Regular labs: CBC, ferritin, CRP, liver enzymes every 1–3 months while adjusting therapy.
• Exercise: Low‑impact activities (walking, swimming, yoga) improve joint mobility and overall health.
• Stress management: Chronic inflammation can be aggravated by stress; mindfulness, meditation, or counseling can be beneficial.
• Support networks: Connect with patient groups (e.g., Still’s Disease Association) for emotional support and up‑to‑date research.

Prevention

Because the exact trigger is unknown, primary prevention is challenging. However, the following strategies may lower the risk of disease flares or complications:

• Prompt treatment of infections—especially viral upper‑respiratory infections—may reduce cytokine storms that could precipitate AOSD.
• Maintain up‑to‑date vaccinations (non‑live vaccines are safe with most immunosuppressives).
• Avoid smoking and limit alcohol, as they can exacerbate systemic inflammation.
• Early referral to a rheumatologist at the first sign of unexplained high‑spiking fevers and rash.

Complications

If left uncontrolled or undertreated, AOSD can lead to serious outcomes.

• Macrophage Activation Syndrome (MAS): A fulminant hyper‑inflammatory state with cytopenias, high ferritin (> 10,000 ng/mL), liver failure, and coagulopathy; mortality can exceed 30 % [5].
• Chronic erosive arthritis: May result in joint deformities and functional disability.
• Organ involvement: Pericarditis, myocarditis, pulmonary fibrosis, or hepatic cirrhosis in rare cases.
• Osteoporosis: Long‑term glucocorticoid use increases fracture risk.
• Infection risk: Immunosuppressive therapy heightens susceptibility to bacterial, viral, and fungal infections.

When to Seek Emergency Care

---

References

1. Mayo Clinic. Adult-onset Still’s disease. https://www.mayoclinic.org. Accessed May 2026.
2. Fautrel B, et al. Adult-onset Still’s disease: 2019 European League Against Rheumatism/American College of Rheumatology recommendations. Ann Rheum Dis. 2020;79:894‑904.
3. Ravelli A, et al. Genetic predisposition in adult-onset Still’s disease. Arthritis Res Ther. 2018;20:192.
4. Yuan H, et al. Efficacy of anakinra in refractory adult-onset Still’s disease: a systematic review. Clin Rheumatol. 2021;40:3179‑3188.
5. Ruscitti P, et al. Macrophage activation syndrome in adult-onset Still disease: clinical features and outcomes. Autoimmun Rev. 2022;21:102825.